Treatment with the MR antagonist esaxerenone abrogated these changes, and led to cerebral and vascular normalization and prolonged subarachnoid hemorrhage-free survival (p < 0.05). The gene discussed is NR3C2; the disease is subarachnoid hemorrhage.